Transvascular lipoprotein transport in patients with chronic renal disease

Jensen, Trine Krogsgaard; Nordestgaard, Borge Gronne; Feldt-Rasmussen, Bo; Jensen, Kurt Svarre; Jensen, Jan Skov
July 2004
Kidney International;Jul2004, Vol. 66 Issue 1, p275
Academic Journal
Transvascular lipoprotein transport in patients with chronic renal disease. Background. While increased plasma cholesterol is a well-established cardiovascular risk factor in the general population, this is not so among patients with chronic renal disease. We hypothesized that the transvascular lipoprotein transport, in addition to the lipoprotein concentration in plasma, determines the degree of atherosclerosis among patients with chronic renal disease. Methods. We used an in vivo method for measurement of transvascular transport of low-density lipoprotein (LDL) in 21 patients with chronic renal disease and in 42 healthy control patients. Autologous 131-iodinated LDL was reinjected intravenously, and the 1-hour fractional escape rate was taken as index of transvascular transport. Results. Transvascular LDL transport tended to be lower in patients with chronic renal disease than in healthy control patients [3.3 (95% CI 2.4–4.2) vs. 4.2 (3.7–4.2)%/hour; NS]. However, this tendency disappeared when transvascular LDL transport was corrected for distribution volume of LDL [1.7 (1.2–2.2) vs. 1.8 (1.6–2.0) %/(hour × (L/m2)); NS]. There was significant variation in transvascular LDL transport between diabetic patients with chronic renal disease, nondiabetic patients with chronic renal disease, and healthy control patients [5.0 (3.2–7.8) vs. 3.0 (2.2–3.8) vs. 4.2 (3.6–4.8) %/hour; P < 0.01 after adjustment for distribution volume of LDL]. This variation was unlikely caused by altered hepatic LDL receptor expression or glycosylation of LDL in diabetes patients. Conclusion. Transvascular LDL transport may be increased in diabetic patients with chronic renal disease, suggesting that lipoprotein flux into the arterial wall is increased. A similar mechanism does not operate in nondiabetic patients with chronic renal disease.


Related Articles

  • Chronic kidney disease induced dysfunction of high density lipoprotein. Yamamoto, Suguru; Kon, Valentina // Clinical & Experimental Nephrology;Apr2014, Vol. 18 Issue 2, p251 

    Traditional risk factors do not account for increased cardiovascular disease in patients with chronic kidney disease (CKD), particularly individuals whose CKD has progressed to end-stage kidney disease requiring dialysis. CKD patients on dialysis show little to no cardiovascular benefits from...

  • Prevalence and risk factors of albuminuria and chronic kidney disease in Chinese population with type 2 diabetes and impaired glucose regulation: Shanghai diabetic complications study (SHDCS). Weiping Jia; Xin Gao; Can Pang; Xuhong Hou; Yuqian Bao; Wei Liu; Wenxia Wang; Yuhua Zuo; Huilin Gu; Kunsan Xiang // Nephrology Dialysis Transplantation;Dec2009, Vol. 24 Issue 12, p3724 

    Background. Diabetes is a major risk factor for the development of kidney disease. We aimed to determine the prevalence of albuminuria and chronic kidney disease (CKD) in Chinese subjects with diabetes and pre-diabetes and the risk factors for kidney disease.

  • Renal endpoints in non-diabetic patients. Oldrizzi, Lamberto; Rugiu, Carlo; de Biase, Vincenzo; Maschio, Giuseppe // Kidney International Supplement;Feb1994, Issue 45, pS-118 

    Focuses on the evaluation of the progression of chronic renal failure in non-diabetic patients. Problems cited by studies on the progression of chronic renal failure; Methods for evaluating renal deterioration; Effects of treatment and other factors with the ability to influence the progression...

  • A1C and Survival in Maintenance Hemodialysis Patients. Kalantar-Zadeh, Kamyar; Kopple, Joel D.; Regidor, Deborah L.; Jing, Jennie; Shinaberger, Christian S.; Aronovitz, Jason; McAllister, Charles J.; Whellan, David; Sharma, Kumar // Diabetes Care;May2007, Vol. 30 Issue 5, p1049 

    OBJECTIVE -- The optimal target for glycemic control has not been established in diabetic dialysis patients. RESEARCH DESIGN AND METHODS --To address this question, the national database of a large dialysis organization (DaVita) was analyzed via time-dependent survival models with repeated...

  • Plasma Lipoprotein(a) Levels Are Associated with Mild Renal Impairment in Type 2 Diabetics Independent of Albuminuria. Lin, Jennie; Reilly, Muredach P.; Terembula, Karen; Wilson, F. Perry // PLoS ONE;Dec2014, Vol. 9 Issue 12, p1 

    Background: CKD, an independent risk factor for CV disease, increases mortality in T2DM. Treating modifiable CV risk factors decreases mortality in diabetics with microalbuminuria, but the role of early CV prevention in diabetics with mild CKD by GFR criteria alone remains unclear. The purpose...

  • One in five with CKD and diabetes are anaemic.  // Pulse;5/7/2008, Vol. 68 Issue 16, p16 

    The article reports on the study which assesses the risk of diabetes and anaemia for patients with chronic kidney disease (CKD) in Great Britain. The study reveals that CKD patients are not at risk of anemia, while diabetics are likely to have earlier stage of CKD. It indicates that one out of...

  • In vivo kinetic studies to further understand pathogenesis of abnormal lipoprotein metabolism in chronic kidney disease. Ikewaki, Katsunori // Clinical & Experimental Nephrology;Apr2014, Vol. 18 Issue 2, p261 

    Patients undergoing hemodialysis (HD) have been shown to be at increased risk for cardiovascular disease (CVD) morbidity and mortality which are, at least in part, due to uremic dyslipidemia including increased triglyceride-rich lipoproteins, in particular remnants, decreased high-density...

  • SLOW PROGRESSION OF CHRONIC KIDNEY DISEASE AND WHAT IT IS ASSOCIATED WITH. N., Eftimovska; O., Stojceva-Taneva; M., Polenakovic // Contributions of Macedonian Academy of Sciences & Arts;2008, Vol. 29 Issue 1, p153 

    Introduction: The risk factors for CKD include diabetes, hyper-tension, smoking, systemic inflammation, obesity, proteinuria, dislipidaemia and anaemia, as well as gender, age, ethnic minority status and positive family history. By screening and adequate treatment of modifiable risk factors we...

  • Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients. Mittman, Neal; Desiraju, Brinda; Fazil, Irfan; Kapupara, Hiteshkumar; Chattopadhyay, Jyoti; Jani, Chinu M.; Avram, Morrell M. // Kidney International Supplement;Aug2010 Supplement 117, Vol. 78, pS41 

    Diabetes is the most common cause of end-stage renal disease and an important risk factor for morbidity and mortality in dialysis patients. Glycemic control, utilizing serial measurement of glycosylated hemoglobin (HbA1c), is generally recommended to limit end-organ damage, including...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics